PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Preferred Specialty Management Policy

- Esbriet® (pirfenidone film-coated tablets and capsules – Genentech, generic and branded generic tablets)

REVIEW DATE: 07/10/2024

OVERVIEW

Pirfenidone, a pyridone, is indicated for the treatment of idiopathic pulmonary fibrosis.[1] Pirfenidone capsules are available in the 267 mg strength as brand and generic products. Pirfenidone film-coated tablets are available as a generic and a brand product in strengths of 267 mg and 801 mg; the 534 mg strength tablet is branded generic pirfenidone.

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of Preferred Products. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The patient is also required to try the Preferred Products. Requests for the Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals for Preferred and Non-Preferred Products are provided for 1 year. If the patient meets the standard *Idiopathic Pulmonary Fibrosis and Related Lung Disease – Pirfenidone Prior Authorization Policy* criteria but has not tried the respective generic Preferred Product, approval for generic Preferred Products will be authorized.

Documentation: Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or other information.

Automation: None.

Preferred Products:	generic pirfenidone tablets (267 mg and 801 mg), generic pirfenidone capsules (267 mg)
Non-Preferred Products:	Esbriet capsules (267 mg), Esbriet tablets (267 mg and 801 mg), branded generic pirfenidone 534 mg tablets

RECOMMENDED EXCEPTION CRITERIA

REFERENCES

1. Esbriet® capsules and film-coated tablets [prescribing information]. South San Francisco, CA: Genentech; February 2023.